Clinical and Analytical Validation of Two Methods for Ki-67 Scoring in Formalin Fixed and Paraffin Embedded Tissue Sections of Early Breast Cancer
Cancers · 03.04.2024 · 16 (7) · 1405
DOI: 10.3390/cancers16071405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 03.04.2024. Verfasst von Snežana Đokić und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Institute of Oncology, 1000 Ljubljana, Slovenia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research Agency.
Abstract (Originalsprache)
Proliferation determined by Ki-67 immunohistochemistry has been proposed as a useful prognostic and predictive marker in breast cancer. However, the clinical validity of Ki-67 is questionable. In this study, Ki-67 was retrospectively evaluated by three pathologists using two methods: a visual assessment of the entire slide and a quantitative assessment of the tumour margin in 411 early-stage breast cancer patients with a median follow-up of 26.8 years. We found excellent agreement between the three pathologists for both methods. The risk of recurrence for Ki-67 was time-dependent, as the high proliferation group (Ki-67 ≥ 30%) had a higher risk of recurrence initially, but after 4.5 years the risk was higher in the low proliferation group. In estrogen receptor (ER)-positive patients, the intermediate Ki-67 group initially followed the high Ki-67 group, but eventually followed the low Ki-67 group. ER-positive pN0-1 patients with intermediate Ki-67 treated with endocrine therapy alone had a similar outcome to patients treated with chemotherapy. A cut-off value of 20% appeared to be most appropriate for distinguishing between the high and low Ki-67 groups. To summarize, a simple visual whole slide Ki-67 assessment turned out to be a reliable method for clinical decision-making in early breast cancer patients. We confirmed Ki-67 as an important prognostic and predictive biomarker.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Institute of Oncology, 1000 Ljubljana, Slovenia.
- Faculty of Medicine Ljubljana, University of Ljubljana, 1000 Ljubljana, Slovenia.
- Department of Cytopathology, Institute of Oncology, 1000 Ljubljana, Slovenia.
- Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
- Department of Medical Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
ORCID-Profile: Simona Miceska, Cvetka Grašič Kuhar, Jera Jeruc
Förderung
- Slovenian Research Agency
Zitieren
APA
Đokić, S., Gazić, B., Grčar Kuzmanov, B., Blazina, J., Miceska, S., Čugura, T., Grašič Kuhar, C., & Jeruc, J. (2024). Clinical and Analytical Validation of Two Methods for Ki-67 Scoring in Formalin Fixed and Paraffin Embedded Tissue Sections of Early Breast Cancer. Cancers, 16(7), 1405. https://doi.org/10.3390/cancers16071405
Vancouver
Đokić S, Gazić B, Grčar Kuzmanov B, Blazina J, Miceska S, Čugura T, et al. Clinical and Analytical Validation of Two Methods for Ki-67 Scoring in Formalin Fixed and Paraffin Embedded Tissue Sections of Early Breast Cancer. Cancers. 2024;16(7):1405. doi:10.3390/cancers16071405
BibTeX
@article{oki2024,
author = {Đokić, Snežana and Gazić, Barbara and Grčar Kuzmanov, Biljana and Blazina, Jerca and Miceska, Simona and Čugura, Tanja and Grašič Kuhar, Cvetka and Jeruc, Jera},
title = {Clinical and Analytical Validation of Two Methods for Ki-67 Scoring in Formalin Fixed and Paraffin Embedded Tissue Sections of Early Breast Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {7},
pages = {1405},
doi = {10.3390/cancers16071405}
}
EUVIMED